Clinical Trial: PIEZO-101 First-in-Human Safety and Proof-of-Concept Study

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07671027) titled 'PIEZO-101 First-in-Human Safety and Proof-of-Concept Study' on June 22.

Brief Summary: The aim of this first-in-human clinical study is to explore the safety, tolerability, pharmacodynamics, and exploratory efficacy of PIEZO-101, an investigational plasmid DNA biostimulator that aims to restore expression of key proteins in the skin for extracellular matrix rejuvenation. PIEZO-101 is administered using an intradermal injection followed by localized electroporation using the investigational device Piezopen. This clinical trial will study safety and tolerability, pharmacodynamics using biopsies from the left knee, and exploratory effi...